Endocrine Abstracts

JOINT443

Introduction: People identifying as transgender continues to increase year after year, and with it, the healthcare services offered to this community. In 2016 our health system established the care program for this population. Its purpose was to standardize healthcare for transgender minors based on the most reliable and solid information currently available. We know trangender medicine could have an impact on health. The analogues of gonadotropin-releasing hormone (aGnRH) are a commonly used treatment to achieve puberty suppression in adolescents who experience gender dysphoria and desire sex reassignment. However, the effect on fertility that their use may have on transgender adolescents remains unknown.

Objective: The aim is to analyze how gonadotropin-releasing hormone analogues impact on the fertility of transgender adolescents undergoing pubertal suppression.

Study Methodology: The study included transgender male adolescents who attended the Gender Diversity unit at Puerta del Mar University Hospital from January 2015 to December 2024 Who had initiated pubertal suppression (PS) with aGnRH. We register Anti-Müllerian Hormone (AMH) available every 6 months after aGnRH initiation during 18 months. Non-parametric statistical tests were performed.

Results: We recruited 38 adolescents. Median current age 15.4 (14.8-16.3 years old. Median PS age was 13.4 (12.2-14.5) years old. 73%has tanner stage 5. We observed no significant changes in AMH in first 18 months after aGnRH initiation (p-value: 0.347). No differences in AMH were observed when comparing PS in tanner 2-3 vs PS in tanner 4-5 (p-value: 0.431).

Conclusions: In our cohort we could establish no relevant changes in AMH after aGnRH initiation. Studies with larger participants could be performed to better support these results.